Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Double-Blind Randomized Clinical Trial of the Efficacy of Venlafaxine Versus Citalopram in the Treatment of the Acute Phase of Major Depressive Disorder

Fatemeh Hosseini 1 , Fariba Amini 1 , Seyed Mojtaba Yassini Ardekani 1 , * , Neda Shariat 1 and Mohammad Nadi 1
Authors Information
1 Department of Psychiatry, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: June 28, 2015, 9 (2)
  • Published Online: June 1, 2015
  • Article Type: Original Article
  • Received: May 16, 2014
  • Revised: July 18, 2014
  • Accepted: August 23, 2014
  • DOI: 10.17795/ijpbs1041

To Cite: Hosseini F, Amini F, Yassini Ardekani S M, Shariat N, Nadi M. Double-Blind Randomized Clinical Trial of the Efficacy of Venlafaxine Versus Citalopram in the Treatment of the Acute Phase of Major Depressive Disorder, Iran J Psychiatry Behav Sci. 2015 ; 9(2):-. doi: 10.17795/ijpbs1041.

Abstract
Copyright © 2015, Mazandaran University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593-602[DOI][PubMed]
  • 2. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol. 2008; 23(3): 113-9[DOI][PubMed]
  • 3. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004; 184: 386-92[PubMed]
  • 4. Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 7[DOI][PubMed]
  • 5. Practice guideline for the treatment of patients with major depressive disorder. 2010;
  • 6. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M, Arias F, Padin J, Martin-Carrasco M, et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26(6): 1129-34[PubMed]
  • 7. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994; 14(6): 419-23[PubMed]
  • 8. Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2009; 259(3): 172-85[DOI][PubMed]
  • 9. Owens MJ, Rosenbaum JF. Escitalopram: a second-generation SSRI. CNS Spectr. 2002; 7(4 Suppl 1): 34-9[PubMed]
  • 10. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000; 58(1): 19-36[PubMed]
  • 11. Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, et al. WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Cochrane Database Syst Rev. 2006; (3)[PubMed]
  • 12. Golden RN, Nicholas L. Antidepressant efficacy of venlafaxine. Depress Anxiety. 2000; 12 Suppl 1: 45-9[PubMed]
  • 13. Sansone RA, Sansone LA. SNRIs pharmacological alternatives for the treatment of obsessive compulsive disorder? Innov Clin Neurosci. 2011; 8(6): 10-4[PubMed]
  • 14. de Silva VA, Hanwella R. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies. Int Clin Psychopharmacol. 2012; 27(1): 8-16[DOI][PubMed]
  • 15. Gharaii B, Mehryar A, Mehrabi F. [Attribution style in patients with anxiety and depression comorbidity] . Iran J Psychiatry Clin Psychol. 2000; 5(4): 37-43
  • 16. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Sogaard J. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry. 2004; 19(12): 1123-30[DOI][PubMed]
  • 17. Gibiino S, Marsano A, Serretti A. Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials. Int J Neuropsychopharmacol. 2014; 17(1): 1-8[DOI][PubMed]
  • 18. Lapmanee S, Charoenphandhu J, Charoenphandhu N. Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors. Behav Brain Res. 2013; 250: 316-25[DOI][PubMed]
  • 19. Li X, Xing B, Yu E, Chen W, Wu H. The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study. J Neuropsychiatry Clin Neurosci. 2013; 25(2): 157-60[DOI][PubMed]
  • 20. Diaz-Martinez A, Benassinni O, Ontiveros A, Gonzalez S, Salin R, Basquedano G, et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther. 1998; 20(3): 467-76[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments